1
|
Gerckens M, Mümmler C, Richard A, Strodel J, Mertsch P, Milger K, Veit T, Gade N, Yildirim AÖ, Schneider C, Kauke T, Michel S, Irlbeck M, Behr J, Kneidinger N. Characterization of Baseline Lung Allograft Dysfunction in Single Lung Transplant Recipients. Transplantation 2025; 109:e213-e221. [PMID: 39250332 DOI: 10.1097/tp.0000000000005189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/11/2024]
Abstract
BACKGROUND Baseline lung allograft dysfunction (BLAD) is characterized by the failure to achieve normal baseline lung function after double lung transplantation (DLTX) and is associated with a high risk of mortality. In single lung transplant (SLTX) recipients, however, cutoff values and associated factors have not been explored. Here, we aimed to define BLAD in SLTX recipients, investigate its impact on allograft survival, and identify potential risk factors for BLAD in SLTX recipients. METHODS We performed a retrospective, single-center analysis of the LTX cohort of LMU Munich between 2010 and 2018. In accordance with DLTX cutoffs, BLAD in SLTX recipients was defined as failure to achieve percentage of forced expiratory volume in 1 s and percentage of forced vital capacity of >60% on 2 consecutive tests >3 wk apart. Survival analysis and regression analysis for potential predictors of BLAD were performed. RESULTS In a cohort of 141 SLTX recipients, 43% of patients met BLAD criteria. SLTX recipients with BLAD demonstrated impaired survival. Native lung hyperinflation was associated with BLAD in obstructive disease, whereas donor/recipient lung size mismatch was associated with BLAD in both obstructive and restrictive underlying diseases. Pulmonary function testing at 3 mo after lung transplantation predicted normal baseline lung function in SLTX recipients with obstructive lung disease. CONCLUSIONS BLAD in SLTX recipients is as relevant as in DLTX recipients and should generally be considered in the follow-up of LTX recipients. Risk factors for BLAD differed between underlying obstructive and restrictive lung disease. A better understanding of associated factors may help in the development of preventive strategies.
Collapse
Affiliation(s)
- Michael Gerckens
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
- Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Carlo Mümmler
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
- Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Alexander Richard
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Johannes Strodel
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Pontus Mertsch
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Katrin Milger
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Tobias Veit
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Nils Gade
- Department of Internal Medicine I, University Hospital, LMU Munich, Munich, Germany
| | - Ali Önder Yildirim
- Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
- Institute of Experimental Pneumology, LMU University Hospital, Ludwig Maximilians University of Munich, LMU Munich, Munich, Germany
| | - Christian Schneider
- Division of Thoracic Surgery, LMU University Hospital, LMU Munich, Munich, Germany
| | - Teresa Kauke
- Division of Thoracic Surgery, LMU University Hospital, LMU Munich, Munich, Germany
| | - Sebastian Michel
- Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
- Department of Cardiac Surgery, LMU University Hospital, LMU Munich, Munich, Germany
| | - Michael Irlbeck
- Department of Anaesthesiology, LMU University Hospital, LMU Munich, Munich, Germany
| | - Jürgen Behr
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
| | - Nikolaus Kneidinger
- Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL), LMU Munich, Munich, Germany
- Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| |
Collapse
|
2
|
Eberlein M, Keech JC, Reed RM. Applied physiological principles in the management of a lung allograft to thoracic cavity size mismatch in severe emphysema. JHLT OPEN 2024; 6:100124. [PMID: 40145029 PMCID: PMC11935444 DOI: 10.1016/j.jhlto.2024.100124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 03/28/2025]
Abstract
In this review, we discuss physiological principles that guided the management of a lung transplant for emphysema related to alpha-1-antitrypsin deficiency, where a lung allograft to thoracic cavity size mismatch occurred (donor-to-recipient predicted total lung capacity [pTLC] ratio was 0.89, donor pTLC-to-recipient actual-TLC ratio 0.62). In emphysema, the loss of lung elastic recoil and airway obstruction leads to air trapping and lung hyperinflation. Remodeling of the thoracic cavity ("barrel chest") develops, which has implications for donor-to-recipient sizing and postoperative management of lung transplantation. We discuss the physiology of a relatively undersized allograft and the impact on chest tube, mechanical ventilation, and respiratory system mechanics management. This case also illustrates how chronic adaptations of the ventilatory pattern to advanced lung diseases are reversible and the chest cavity size can remodel back to normal after lung transplantation.
Collapse
Affiliation(s)
- Michael Eberlein
- Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland
| | - John C. Keech
- Department of Cardiothoracic Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa
| | - Robert M. Reed
- Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland
| |
Collapse
|
3
|
Keller MB, Sun J, Alnababteh M, Ponor L, D. Shah P, Mathew J, Kong H, Charya A, Luikart H, Aryal S, Nathan SD, Orens JB, Khush KK, Kyoo Jang M, Agbor-Enoh S. Baseline Lung Allograft Dysfunction After Bilateral Lung Transplantation Is Associated With an Increased Risk of Death: Results From a Multicenter Cohort Study. Transplant Direct 2024; 10:e1669. [PMID: 38953039 PMCID: PMC11216668 DOI: 10.1097/txd.0000000000001669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Revised: 05/02/2024] [Accepted: 05/04/2024] [Indexed: 07/03/2024] Open
Abstract
Background A prior single-center, retrospective cohort study identified baseline lung allograft dysfunction (BLAD) as a risk factor for death in bilateral lung transplant recipients. In this multicenter prospective cohort study, we test the association of BLAD with death in bilateral lung transplant recipients, identify clinical risk factors for BLAD, and assess its association with allograft injury on the molecular level. Methods This multicenter, prospective cohort study included 173 bilateral lung transplant recipients that underwent serial pulmonary function testing and plasma collection for donor-derived cell-free DNA at prespecified time points. BLAD was defined as failure to achieve ≥80% predicted for both forced expiratory volume in 1 s and forced vital capacity after lung transplant, on 2 consecutive measurements at least 3 mo apart. Results BLAD was associated with increased risk of death (hazard ratio, 1.97; 95% confidence interval [CI], 1.05-3.69; P = 0.03) but not chronic lung allograft dysfunction alone (hazard ratio, 1.60; 95% CI, 0.87-2.95; P = 0.13). Recipient obesity (odds ratio, 1.69; 95% CI, 1.15-2.80; P = 0.04) and donor age (odds ratio, 1.03; 95% CI, 1.02-1.05; P = 0.004) increased the risk of developing BLAD. Patients with BLAD did not demonstrate higher log10(donor-derived cell-free DNA) levels compared with no BLAD (slope [SE]: -0.0095 [0.0007] versus -0.0109 [0.0007]; P = 0.15). Conclusions BLAD is associated with an increased risk of death following lung transplantation, representing an important posttransplant outcome with valuable prognostic significance; however, early allograft specific injury on the molecular level does not increase the risk of BLAD, supporting further mechanistic insight into disease pathophysiology.
Collapse
Affiliation(s)
- Michael B. Keller
- Laborarory of Applied Precision Omics (APO), National Institutes of Health, Bethesda, MD
- Laboratory of Transplantation Genomics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Junfeng Sun
- Advanced Lung Disease Program and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA
| | - Muhtadi Alnababteh
- Laborarory of Applied Precision Omics (APO), National Institutes of Health, Bethesda, MD
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Lucia Ponor
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
| | - Pali D. Shah
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD
| | - Joby Mathew
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD
| | - Hyesik Kong
- Laborarory of Applied Precision Omics (APO), National Institutes of Health, Bethesda, MD
- Laboratory of Transplantation Genomics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
| | - Ananth Charya
- Division of Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD
| | - Helen Luikart
- Genome Transplant Genomics (GTD), Stanford University School of Medicine, Palo Alto, CA
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA
- Department of Pathology, Stanford University School of Medicine, Palo Alto, CA
| | - Shambhu Aryal
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Advanced Lung Disease Program and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA
| | - Steven D. Nathan
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Advanced Lung Disease Program and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA
| | - Jonathan B. Orens
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD
| | - Kiran K. Khush
- Genome Transplant Genomics (GTD), Stanford University School of Medicine, Palo Alto, CA
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA
| | - Moon Kyoo Jang
- Laborarory of Applied Precision Omics (APO), National Institutes of Health, Bethesda, MD
- Laboratory of Transplantation Genomics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
| | - Sean Agbor-Enoh
- Laborarory of Applied Precision Omics (APO), National Institutes of Health, Bethesda, MD
- Laboratory of Transplantation Genomics, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD
- Genomic Research Alliance for Transplantation (GRAfT), Bethesda, MD
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD
| |
Collapse
|
4
|
Mody S, Nadkarni S, Vats S, Kumar A, Nandavaram S, Keshavamurthy S. Lung Donor Selection and Management: An Updated Review. OBM TRANSPLANTATION 2023; 07:1-54. [DOI: 10.21926/obm.transplant.2304203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2025]
Abstract
The shortage of donor lungs for transplantation is a major challenge, resulting in longer waitlist times for patients with a higher risk of waitlist mortality. It is crucial to continue promoting awareness about organ donation through legislation, public campaigns, and health care provider education. Only a small number of cadaveric donors meet the ideal criteria for lung donation, leaving many lungs unused. Donor lung utilization can be improved by carefully considering the extended-criteria donors, actively participating in donor management, and by utilizing the modalities to assess and manage the marginal lungs after retrieval from the donor. The purpose of this article is to provide an up-to-date review of donor selection, assessment of donor lungs, and donor lung management to enhance organ recovery rates for lung transplantation.
Collapse
|
5
|
Yu WS, Son J. Donor Selection, Management, and Procurement for Lung Transplantation. J Chest Surg 2022; 55:277-282. [PMID: 35924533 PMCID: PMC9358168 DOI: 10.5090/jcs.22.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 07/18/2022] [Indexed: 11/16/2022] Open
Abstract
Lung transplantation is a life-saving procedure in patients with end-stage lung disease. However, it inherently depends on the availability of donor organs. The selection of suitable lungs for transplantation, management of donors to minimize further injury and improve organ function, and safe procurement remain critical for successful transplantation. In this review, we provide an update on the current understanding of donor selection, management, and lung procurement.
Collapse
Affiliation(s)
- Woo Sik Yu
- Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, Suwon, Korea
| | - JeongA Son
- Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, Suwon, Korea
| |
Collapse
|